Pure Global
NCT06040346

Open-Label Study to Assess Meplazumab in Adult Patients Diagnosed With Plasmodium Falciparum

A Phase 2a, Multicenter, Open-label, Dose-finding, Dose Escalation Study of Meplazumab in Adult Patients Diagnosed With Uncomplicated Plasmodium Falciparum Malaria
Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd·Phase 2·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Malaria
Drug/Device/Intervention
Meplazumab for Injection
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd
Timeline & enrollment
Phase
Phase 2
Start date
Dec 15, 2023
End date
Sep 09, 2024
Enrollment
60 participants
Primary outcome

The Number of participants with Drug-related SAE, All-cause SAE, Drug-related AESI, All-cause AESI.,The Number of Participants discontinuation/ withdrawals due to AE

Summary

This phase 2a open-label study to assess Meplazumab in adult patients diagnosed with
 Plasmodium falciparum

ICD-10 classifications
Unspecified malariaPlasmodium malariae malariaPlasmodium falciparum malariaOther parasitologically confirmed malariaPlasmodium ovale malaria
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06040346
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06040346 through Pure Global AI's free database. This Phase 2 trial is sponsored by Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd and is currently Not yet recruiting. The study focuses on Malaria. Target enrollment is 60 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.